Which pharmaceutical company produces avatrombopag tablets?

Avatrombopag (Avatrombopag) tablets are an oral thrombopoietic drug, mainly used to treat patients with thrombocytopenia associated with chronic liver disease, especially to reduce the risk of blood transfusions when these patients require elective surgery. The drug stimulates the proliferation and differentiation of megakaryocytes in the bone marrow by activating the thrombopoietin receptor (TPO-R), thereby increasing platelet levels and reducing the occurrence of bleeding complications.

Avatrombopag was originally developed by the American company Dova Pharmaceuticals, which has a certain influence in the field of hematology drug development. Later, Dova Pharmaceuticals was acquired by Sobi, a subsidiary of the large Swiss pharmaceutical company Novartis (Novartis) in 2019. Therefore, Sobi is responsible for the production and global promotion of the original avatrombopag currently sold in the international market. Its product name is "Doptelet".

In the Chinese market, avatrombopag has been approved for marketing by the State Food and Drug Administration and has been included in the medical insurance catalog. In China, Takeda Pharmaceutical (China) Co., Ltd. is the licensee of this drug for sales and distribution. The specification is 20mg tablets. Patients can obtain prescriptions through regular hospital pharmacies and enjoy a certain level of medical insurance reimbursement. The price will vary slightly depending on regional policies.

In addition, there are also generic versions approved for marketing overseas in countries such as Laos and Bangladesh. The price is relatively cheap and the ingredients are consistent with the original drug. Most of these generic drugs are produced by well-known local generic drug manufacturers, and the price is only a fraction of the original drugs, providing an economical choice for patients who cannot afford high-priced drugs. When choosing drugs, it is recommended that patients weigh the efficacy, risks and affordability under the guidance of a doctor and make a treatment decision that suits them.

Reference materials:https://go.drugbank.com/drugs/DB11995